BNY Mellon Small Cap Value Fund outperformed its benchmark in Q2 2026 amid resilient economic growth. Read the full analysis ...

Dianthus estimates that existing immunoglobulin and biologic treatment in CIDP represents more than $3.5 billion. In addition ...

Global M&A activity surged 48% in H1 2026, creating a robust backdrop for merger arbitrage. Read the full analysis for more ...

The Emerging Markets Voya High Dividend Equity Fund underperformed its benchmark in Q2 2026 despite strong global gains. Read ...

Touchstone U.S. Quality Bond Fund outperformed its benchmark in Q2 2026 amid energy-driven inflation. Read the full analysis ...

Now, on a trailing twelve-month basis, FCF-to-shareholder returns are still exceeding their long-term target at over 85%. In ...

For International segment sales, they reported 11% of constant currency growth back in Q1. In Q2, foreign exchange seemed to ...

Nomura Science and Technology Fund outperformed in Q2 2026, gaining from AI infrastructure and storage demand. Read the full ...

Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite ...

M all-cash MicroAge acquisition represents about 20% of ScanSource's market cap, but limited financial disclosure clouds ...

CME Group remains a Buy: record Q2 2026 revenues, ~70% margins, and catalysts like 24/7 trading and Treasury Link. Read here ...

The Wasatch Frontier Emerging Small Countries Fund returned 6.88% in Q2 2026, lagging its benchmark. Read the full analysis ...